Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19

NCT04346199 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04346199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04346199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2020
Completion date
November 17, 2020
Enrollment
177 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19